<DOC>
	<DOCNO>NCT01403025</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial assess incidence rate type SADRs ( serious adverse drug reaction ) .</brief_summary>
	<brief_title>Evaluating Safety Effectiveness Liraglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus , include newlydiagnosed subject , require treatment liraglutide Subjects previously liraglutide Subjects previously enrol study Subjects hypersensitivity liraglutide excipients Subjects pregnant , breast feeding intention become pregnant within study period Subjects cancer ( except basal cell skin cancer squamous cell skin cancer ) clinically significant disorder , except condition associate type 2 diabetes mellitus history physician ' opinion could interfere result trial Known suspect abuse alcohol narcotic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>